Orthopedic Biomaterials Market Report Suite - Japan - 2020 - 2026

Throughout this medical market research, the publisher analyzed 16 orthobiologics companies in Japan and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.

While this MedSuite report contains all of the Japanese Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.

Markets Covered

Procedure Volumes for the Japanese Orthopedic Biomaterials Devices – MedPro
Orthopedic Bone Graft Substitute Market - MedCore
Hyaluronic Acid Viscosupplementation Market - MedCore

Japanese Orthopedic Biomaterials Market Insights

A lack of product differentiation across similar injection cycle products has led to commoditization, which has stifled innovation and the further development of new products. The prices of HA viscosupplementation products in Japan have drastically decreased since their introduction and are among the lowest in the world.

In August 2018, Medtronic received PMDA approval for its Grafton® DBM allograft product, which is the first DBM allograft to be approved in Japan. Grafton® was commercially launched in February 2019. Growth of this product will be primarily driven by spine procedures and other orthopedic procedures that it is indicated for.

Overall, the Japanese orthopedic biomaterials market was valued at $426.9 million in 2019. This is expected to fluctuate over the forecast period with a -0.4% CAGR.

LIST OF FIGURESLIST OF CHARTSEXECUTIVE SUMMARYJAPANESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEWCOMPETITIVE ANALYSISMARKET TRENDSMARKET DEVELOPMENTSPROCEDURE NUMBERSMARKETS INCLUDEDVERSION HISTORY

RESEARCH METHODOLOGY

Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

PRODUCT ASSESSMENT

2.1 INTRODUCTION
2.2 PRODUCT PORTFOLIOS
2.2.1 Bone Graft Substitutes
2.2.2 Growth Factors
2.2.2.1 Other Products
2.2.3 Hyaluronic Acid Viscosupplementation (HAV)
2.3 REGULATORY ISSUES AND RECALLS
2.3.1 Bone Graft Substitutes
2.3.1.1 Allografts
2.3.1.1.1 MTF
2.3.1.2 DBM
2.3.1.2.1 AlloSource
2.3.1.2.2 SeaSpine
2.3.1.2.3 RTI Surgical
2.3.1.3 Synthetics
2.3.1.3.1 Abyrx
2.3.1.3.2 Zimmer Biomet
2.3.2 Growth Factors
2.3.2.1.1 Medtronic
2.3.3 Hyaluronic Acid Viscosupplementation
2.3.3.1 Three-injection
2.3.3.1.1 Ferring Pharmaceuticals
2.4 CLINICAL TRIALS
2.4.1 Bone Graft Substitutes
2.4.1.1 Allografts
2.4.1.1.1 Providence Medical Technology
2.4.1.1.2 The University of Texas Health Science
2.4.1.1.3 University of Winchester
2.4.1.2 BDM
2.4.1.2.1 K2M
2.4.1.2.2 Zimmer Biomet
2.4.1.3 Synthetics
2.4.1.3.1 Baxter
2.4.1.3.2 Bonesupport
2.4.1.3.3 DePuy Synthes
2.4.1.3.4 NuVasive
2.4.1.3.5 RTI surgical
2.4.1.3.6 Sunstar GUIDOR
2.4.1.4 Other materials and comparison
2.4.1.4.1 Seoul National University Hospital.
2.4.1.4.2 Sewon Cellontech
2.4.1.4.3 SurgaColl Technologies Limited
2.4.1.4.4 University of Colorado
2.4.1.4.5 University of Padova
2.4.2 Growth Factors
2.4.2.1.1 Bioventus
2.4.2.1.2 Cerapedics
2.4.2.1.3 CGBio
2.4.2.1.4 Isto
2.4.2.1.5 Medtronic
2.4.2.1.6 NuVasive
2.4.2.1.7 Wright
2.4.2.1.8 Others
2.4.3 Hyaluronic Acid Viscosupplementation
2.4.3.1.1 Anika Therapeutics
2.4.3.1.2 Bioventus
2.4.3.1.3 Cairo University
2.4.3.1.4 Ferring Pharmaceuticals
2.4.3.1.5 Federal University of Minas Gerais
2.4.3.1.6 Fidia Pharma USA Inc.
2.4.3.1.7 Istituto Ortopedico Rizzoli
2.4.3.1.8 University Hospital
2.4.3.1.9 Universidade Nova de Lisboa

JAPAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

3.1 INTRODUCTION
3.1.1 Bone Graft Substitutes
3.1.2 Growth Factors
3.1.3 Hyaluronic Acid (HA) Viscosupplementation
3.2 CURRENCY EXCHANGE RATE
3.3 MARKET OVERVIEW AND TREND ANALYSIS
3.4 DRIVERS AND LIMITERS
3.4.1 Market Drivers
3.4.2 Market Limiters
3.5 COMPETITIVE MARKET SHARE ANALYSIS
3.6 MERGERS AND ACQUISITIONS
3.7 COMPANY PROFILES
3.7.1 Anika Therapeutics
3.7.2 Bioventus
3.7.3 DePuy Synthes
3.7.4 Ferring Pharmaceuticals
3.7.5 Fidia Pharmaceuticals
3.7.6 Genzyme (Sanofi Group)
3.7.7 Harvest Technologies (Terumo BCT)
3.7.8 Integra LifeSciences
3.7.9 Medtronic
3.7.10 Musculoskeletal Transplant Foundation (MTF)
3.7.11 NuVasive
3.7.12 Orthofix
3.7.13 RTI Surgical
3.7.14 Stryker
3.7.15 Vericel Corporation (formerly Aastrom Bioscience)
3.7.16 Zimmer Biomet
3.8 SWOT ANALYSIS
3.8.1 Anika Therapeutics
3.8.2 Bioventus
3.8.3 DePuy Synthes
3.8.4 Ferring Pharmaceuticals
3.8.5 Fidia Pharmaceuticals
3.8.7 Harvest Technologies (Terumo BCT)
3.8.8 Integra LifeSciences
3.8.9 Medtronic
3.8.10 Musculoskeletal Transplant Foundation (MTF)
3.8.11 NuVasive
3.8.12 Orthofix
3.8.14 Stryker
3.8.15 Vericel Corporation (formerly Aastrom Bioscience)
3.8.16 Zimmer Biomet

PROCEDURE NUMBERS

4.1 INTRODUCTION
4.2 PROCEDURES
4.2.1 Orthopedic Biomaterial Procedures by Segment
4.2.2 Orthopedic Bone Grafting Procedures
4.2.2.1 Units per Procedure by Indication
4.2.2.2 Autograft Orthopedic Bone Grafting Procedures by Indication
4.2.2.3 Synthetic Orthopedic Bone Grafting Procedures by Indication
4.2.3 Hyaluronic Acid Supplementation Procedures
4.2.3.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

5.1 INTRODUCTION
5.2 MARKET ANALYSIS AND FORECAST
5.2.1.1 Synthetic Bone Graft Substitute Market
5.2.1.1.1 Synthetic Bone Graft Substitute Market by Indication
5.2.1.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
5.3 DRIVERS AND LIMITERS
5.3.1 Market Drivers
5.3.2 Market Limiters
5.4 COMPETITIVE MARKET SHARE ANALYSIS

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

6.1 INTRODUCTION
6.1.1 Benefits of Viscosupplementation
6.1.2 Synovial Fluid
6.2 MARKET OVERVIEW
6.3 MARKET ANALYSIS AND FORECAST
6.3.1 Total Hyaluronic Acid Viscosupplementation Market
6.3.2 Three-Injection Hyaluronic Acid Viscosupplementation Market
6.3.3 Five-Injection Hyaluronic Acid Viscosupplementation Market
6.4 DRIVERS AND LIMITERS
6.4.1 Market Drivers
6.4.2 Market Limiters
6.5 COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS